Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Xiaotian Zhang(Peking University), Jiafu Ji(Peking University), Baoqing Jia(Chinese PLA General Hospital), Yanong Wang(Shanghai Medical College of Fudan University), Dan Wu(Nanjing Drum Tower Hospital), Yanbing Zhou(Qingdao University), Xiangji Ying(University of North Carolina at Chapel Hill), Aiwen Wu(Peking University), Xinbao Wang(Capital University), Lianhai Zhang(Mount Sinai Hospital), Zhiwei Zhou(Sun Yat-sen University), Yihong Sun(South China Agricultural University), Changsong Qi(Peking University), Jiren Yu(Hangzhou First People's Hospital), Leping Li(Shandong University), Xiaojiang Wu(Ministry of Education), Ze-Ning Huang(Fujian Medical University), Peiwu Yu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Yingjiang Ye(Peking University), Lin Shen(Peking University), E Jian‐Yu(Johns Hopkins University), Huanqiu Chen(Jiangsu Cancer Hospital), Yuxian Bai(Harbin Medical University), Zhaode Bu(Peking University), Xin Wang(Jiangsu University), Yong Li(Hebei Medical University), Li Chen(University of Macau), Huimian Xu(First Hospital of China Medical University), Lin Chen(Chinese PLA General Hospital), Yian Du(Zhejiang Cancer Hospital), Zhongtao Zhang(Capital Medical University), Chen Yao(Peking University), Yingwei Xue(Harbin Medical University), Fei Li(Xiamen Medical College), Ziyu Li(Peking University), Jian Suo(Jilin University), Yulong He(Sun Yat-sen University), Yannan Yuan(Peking University), Guanbao Zhu(Wenzhou Medical University), Ming Cui(Peking University), Guoli Li(Nanjing General Hospital of Nanjing Military Command), Gang Xiao(Sichuan University), Xiangqian Su(Peking University), Liang Han(Tianjin Medical University Cancer Institute and Hospital), Chengxue Dang(First Affiliated Hospital of Xi'an Jiaotong University)
Cited by 436
Related Papers
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k